| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3499 | 2019 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3228 | 2017 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2328 | 2017 |
| Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology JS Damrauer, KA Hoadley, DD Chism, C Fan, CJ Tiganelli, SE Wobker, ... Proceedings of the national academy of sciences 111 (8), 3110-3115, 2014 | 978 | 2014 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 758 | 2018 |
| Genome sequencing identifies a basis for everolimus sensitivity G Iyer, AJ Hanrahan, MI Milowsky, H Al-Ahmadie, SN Scott, ... Science 338 (6104), 221-221, 2012 | 732 | 2012 |
| Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma EM Van Allen, KW Mouw, P Kim, G Iyer, N Wagle, H Al-Ahmadie, C Zhu, ... Cancer discovery 4 (10), 1140-1153, 2014 | 638 | 2014 |
| Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ... Nature 518 (7538), 240-244, 2015 | 609 | 2015 |
| Genome doubling shapes the evolution and prognosis of advanced cancers CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ... Nature genetics 50 (8), 1189-1195, 2018 | 576 | 2018 |
| Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers MY Teo, K Seier, I Ostrovnaya, AM Regazzi, BE Kania, MM Moran, ... Journal of Clinical Oncology 36 (17), 1685-1694, 2018 | 485 | 2018 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 436 | 2022 |
| Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets EJ Pietzak, A Bagrodia, EK Cha, EN Drill, G Iyer, S Isharwal, I Ostrovnaya, ... European urology 72 (6), 952-959, 2017 | 358 | 2017 |
| Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer G Iyer, H Al-Ahmadie, N Schultz, AJ Hanrahan, I Ostrovnaya, AV Balar, ... Journal of Clinical Oncology 31 (25), 3133-3140, 2013 | 344 | 2013 |
| Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis A Snyder, T Nathanson, SA Funt, A Ahuja, J Buros Novik, MD Hellmann, ... PLoS medicine 14 (5), e1002309, 2017 | 313 | 2017 |
| Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer T Powles, BP Valderrama, S Gupta, J Bedke, E Kikuchi, ... New England Journal of Medicine 390 (10), 875-888, 2024 | 295 | 2024 |
| DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma MY Teo, RM Bambury, EC Zabor, E Jordan, H Al-Ahmadie, ME Boyd, ... Clinical cancer research 23 (14), 3610-3618, 2017 | 274 | 2017 |
| Genomic characterization of upper tract urothelial carcinoma JP Sfakianos, EK Cha, G Iyer, SN Scott, EC Zabor, RH Shah, Q Ren, ... European urology 68 (6), 970-977, 2015 | 255 | 2015 |
| BRAF mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer RN Grisham, G Iyer, K Garg, D DeLair, DM Hyman, Q Zhou, A Iasonos, ... Cancer 119 (3), 548-554, 2013 | 239 | 2013 |
| Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma F Audenet, S Isharwal, EK Cha, MTA Donoghue, EN Drill, I Ostrovnaya, ... Clinical Cancer Research 25 (3), 967-976, 2019 | 226 | 2019 |
| Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer HA Al-Ahmadie, G Iyer, BH Lee, SN Scott, R Mehra, A Bagrodia, ... Nature genetics 48 (4), 356-358, 2016 | 195 | 2016 |
David SolitCo-Director, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterZweryfikowany adres z mskcc.org
